NuCana plc has announced significant preclinical data indicating that its drug candidate, NUC-7738, enhances the anti-cancer activity of carfilzomib, a proteasome inhibitor used in treating multiple myeloma. This revelation was made during the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics held in Barcelona, Spain, from November 18-20, 2026. The findings are essential as they may lead to improved treatment options for patients suffering from this aggressive form of cancer.

NuCana plc, listed on Nasdaq under the ticker NCNA, is a clinical-stage biopharmaceutical company focused on advancing cancer treatments through its proprietary ProTide technology. The company aims to enhance the effectiveness of existing chemotherapy agents, particularly nucleoside analogs, which are widely used but often have significant limitations. The recent filing, dated November 20, 2026, marks a pivotal moment for NuCana as it seeks to leverage its innovative approach to improve patient outcomes.

The filing reveals that NUC-7738 demonstrated single-agent activity and significantly boosted the anti-cancer effects of carfilzomib across multiple myeloma cell lines. In tests, the combination treatment reduced cell viability to as low as 3% in two models, compared to approximately 50% viability when each drug was used alone. These results provide a strong scientific rationale for NuCana to further investigate this combination therapy in clinical settings.

According to the filing, the combination of NUC-7738 and carfilzomib not only enhanced cancer cell death but also altered proteasome function, increasing the inhibition achieved with carfilzomib. This suggests that NUC-7738 may play a crucial role in making cancer cells more susceptible to treatment, which is particularly vital for patients with multiple myeloma who rely heavily on proteasome inhibitors for their therapy.

The implications of this data extend beyond multiple myeloma. NuCana's research indicates that NUC-7738 may also have potential applications across various cancer types. In a broader laboratory screen, carfilzomib ranked highly in combination activity with NUC-7738 across multiple solid tumor models, indicating its versatility as a treatment option.

Hugh S. Griffith, Founder and CEO of NuCana, expressed optimism about the findings, stating, "These findings add an important dimension to our understanding of NUC-7738's mode of action. We believe these data strengthen the rationale for further evaluation of NUC-7738 in combination with proteasome inhibitors and across additional tumor types." Griffith also highlighted the company's commitment to defining the optimal clinical development path for NUC-7738, particularly in light of upcoming Phase 2 results.

NuCana's strategic direction includes ongoing discussions with the FDA regarding a potential registrational strategy for NUC-7738, which could pave the way for future approvals and market entry. The company anticipates that its current cash resources will support operations into 2029, allowing it to focus on advancing its clinical programs and exploring new indications for its drug candidates.

As NuCana prepares to present further results from its Phase 2 expansion cohort of the NuTide:701 study, which evaluates NUC-7738 in combination with pembrolizumab for patients with PD-1 inhibitor-resistant metastatic melanoma, the industry will be watching closely. This upcoming presentation at the ESMO Immuno-Oncology & Advanced Therapies Congress in London from December 14-16, 2026, will provide additional insights into the drug's potential and its role in the evolving landscape of cancer treatment.

The recent developments surrounding NUC-7738 underscore NuCana's position as a key player in the pharmaceutical preparations industry, particularly in the fight against cancer. As the company continues to unveil promising data, it may influence treatment protocols and competitive dynamics in the oncology sector.